BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 26503109)

  • 1. Influence of 1 year of androgen deprivation therapy on lipid and glucose metabolism and fat accumulation in Japanese patients with prostate cancer.
    Mitsuzuka K; Kyan A; Sato T; Orikasa K; Miyazato M; Aoki H; Kakoi N; Narita S; Koie T; Namima T; Toyoda S; Fukushi Y; Habuchi T; Ohyama C; Arai Y; ;
    Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):57-62. PubMed ID: 26503109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of androgen deprivation therapy on lipid metabolism and body composition in Japanese patients with prostate cancer.
    Torimoto K; Samma S; Kagebayashi Y; Chihara Y; Tanaka N; Hirayama A; Fujimoto K; Hirao Y
    Jpn J Clin Oncol; 2011 Apr; 41(4):577-81. PubMed ID: 21297122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intermittent androgen deprivation in prostate cancer patients: factors predictive of prolonged time off therapy.
    Strum SB; Scholz MC; McDermed JE
    Oncologist; 2000; 5(1):45-52. PubMed ID: 10706649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic changes with degarelix vs leuprolide plus bicalutamide in patients with prostate cancer: a randomized clinical study.
    Sawazaki H; Araki D; Kitamura Y; Yagi K
    World J Urol; 2020 Jun; 38(6):1465-1471. PubMed ID: 31482294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined androgen blockade (CAB) versus luteinizing hormone-releasing hormone (LHRH) agonist monotherapy for androgen deprivation therapy.
    Park HS; Shin HB; Woo SH; Jeon SH; Lee SH; Kang SH; Shim JS; Shin DW; Park J
    World J Urol; 2020 Apr; 38(4):971-979. PubMed ID: 31187203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic effects of androgen deprivation therapy.
    Choi SM; Kam SC
    Korean J Urol; 2015 Jan; 56(1):12-8. PubMed ID: 25598932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study of testosterone-guided androgen deprivation therapy in management of prostate cancer.
    Niraula S; Templeton AJ; Vera-Badillo FE; Joshua AM; Sridhar SS; Cheung PW; Yip PM; Dodd A; Nugent Z; Tannock IF
    Prostate; 2016 Feb; 76(2):235-42. PubMed ID: 26768279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters.
    Yannucci J; Manola J; Garnick MB; Bhat G; Bubley GJ
    J Urol; 2006 Aug; 176(2):520-5. PubMed ID: 16813881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic consequences of gonadotropin-releasing hormone agonists vs orchiectomy: a randomized clinical study.
    Østergren PB; Kistorp C; Fode M; Bennedbaek FN; Faber J; Sønksen J
    BJU Int; 2019 Apr; 123(4):602-611. PubMed ID: 30388320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of concurrent weekly docetaxel, high-dose intensity-modulated radiation therapy (IMRT) and androgen-deprivation therapy (ADT) for high-risk prostate cancer.
    Chen RC; Rosenman JG; Hoffman LG; Chiu WK; Wang AZ; Pruthi RS; Wallen EM; Crane JM; Kim WY; Rathmell WK; Godley PA; Whang YE
    BJU Int; 2012 Dec; 110(11 Pt B):E721-6. PubMed ID: 23016517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
    Wadhwa VK; Weston R; Mistry R; Parr NJ
    BJU Int; 2009 Sep; 104(6):800-5. PubMed ID: 19338564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The metabolic syndrome and its components in patients with prostate cancer on androgen deprivation therapy.
    Morote J; Gómez-Caamaño A; Alvarez-Ossorio JL; Pesqueira D; Tabernero A; Gómez Veiga F; Lorente JA; Porras M; Lobato JJ; Ribal MJ; Planas J;
    J Urol; 2015 Jun; 193(6):1963-9. PubMed ID: 25541340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of androgen deprivation therapy in the thyroid function test of patients with prostate cancer.
    Morote J; Esquena S; Orsola A; Salvador C; Trilla E; Cecchini L; Raventós CX; Planas J; Catalán R; Reventós J
    Anticancer Drugs; 2005 Sep; 16(8):863-6. PubMed ID: 16096434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment and Management of Cardiovascular Risk Factors Among US Veterans With Prostate Cancer.
    Sun L; Parikh RB; Hubbard RA; Cashy J; Takvorian SU; Vaughn DJ; Robinson KW; Narayan V; Ky B
    JAMA Netw Open; 2021 Feb; 4(2):e210070. PubMed ID: 33625512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between bone mineral density and androgen-deprivation therapy in Japanese prostate cancer patients.
    Yuasa T; Maita S; Tsuchiya N; Ma Z; Narita S; Horikawa Y; Yamamoto S; Yonese J; Fukui I; Takahashi S; Hatake K; Habuchi T
    Urology; 2010 May; 75(5):1131-7. PubMed ID: 20163839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of androgen deprivation therapy on arterial stiffness and serum lipid profile changes in patients with prostate cancer: a prospective study of initial 6-month follow-up.
    Oka R; Utsumi T; Endo T; Yano M; Kamijima S; Kamiya N; Shirai K; Suzuki H
    Int J Clin Oncol; 2016 Apr; 21(2):389-396. PubMed ID: 26296528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the lipid profile and atherogenic risk during androgen deprivation therapy in prostate cancer patients.
    Salvador C; Planas J; Agreda F; Placer J; Trilla E; Lopez MA; Morote J
    Urol Int; 2013; 90(1):41-4. PubMed ID: 23235105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physical function changes in prostate cancer patients on androgen deprivation therapy: a 2-year prospective study.
    Levy ME; Perera S; van Londen GJ; Nelson JB; Clay CA; Greenspan SL
    Urology; 2008 Apr; 71(4):735-9. PubMed ID: 18279933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin-like growth factor-1 is associated with regulation of the luteinizing hormone production in men receiving androgen deprivation therapy with gonadotropin-releasing hormone analogues for localized prostate cancer.
    Hara N; Takizawa I; Isahaya E; Nishiyama T; Hoshii T; Ishizaki F; Takahashi K
    Urol Oncol; 2012 Sep; 30(5):596-601. PubMed ID: 21458314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.